2016
Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction
Lopes RD, Pieper KS, Stevens SR, Solomon SD, McMurray JJ, Pfeffer MA, Leimberger JD, Velazquez EJ. Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction. Journal Of The American Heart Association 2016, 5: e003045. PMID: 27353607, PMCID: PMC4937254, DOI: 10.1161/jaha.115.003045.Peer-Reviewed Original ResearchConceptsVentricular systolic dysfunctionHeart failureMyocardial infarctionIntegrated discrimination improvementSystolic dysfunctionCardiovascular deathMultivariable Cox proportional hazardsAcute Myocardial Infarction trialNet reclassification improvement indexNonfatal heart failureMyocardial Infarction trialNonfatal myocardial infarctionPredictors of mortalityPatient informationBaseline heart rateAcute myocardial infarctionCox proportional hazardsCreatinine clearanceHospital arrivalHospital dischargeIndex hospitalizationPatient characteristicsOverall mortalityIndex eventClinical eventsEffect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT
Abdul-Rahim AH, Docherty KF, Skali H, Køber L, Dickstein K, Maggioni AP, Mareev V, Zannad F, Velazquez EJ, Califf RM, Pfeffer MA, Solomon SD, Lees KR, McMurray JJ. Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. European Stroke Journal 2016, 1: 93-100. PMID: 31008270, PMCID: PMC6301225, DOI: 10.1177/2396987316646025.Peer-Reviewed Original ResearchAngiotensin receptor blockersRisk of strokeAcute myocardial infarctionMyocardial infarctionReceptor blockersDual renin-angiotensin system blockadeEnzyme inhibitorsDual renin-angiotensin blockadeRenin-angiotensin system blockadeAcute Myocardial Infarction trialCox proportional hazards regressionRenin-angiotensin blockadeMyocardial Infarction trialRate of strokeVentricular systolic dysfunctionProportional hazards regressionRenin inhibitor aliskirenSystem blockadeSystolic dysfunctionHazard ratioHeart failureTreatment groupsPatientsDiabetesStroke
2015
Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Lam CS, McEntegart M, Claggett B, Liu J, Skali H, Lewis E, Køber L, Rouleau J, Velazquez E, Califf R, McMurray JJ, Pfeffer M, Solomon S. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal Of Heart Failure 2015, 17: 301-312. PMID: 25655011, DOI: 10.1002/ejhf.238.Peer-Reviewed Original ResearchConceptsAcute Myocardial Infarction trialMyocardial Infarction trialVentricular systolic dysfunctionHeart failureMyocardial infarctionSystolic dysfunctionClinical characteristicsVentricular volumeKillip class III/IVLeft ventricular systolic dysfunctionRisk of HFClass III/IVHigher long-term riskSmaller left ventricular volumesSimilar ejection fractionLong-term mortalityPost-infarction anginaRisk of hospitalizationSubset of patientsNon-fatal outcomesLong-term riskLeft ventricular volumeAssociation of sexMore comorbiditiesCardiovascular death
2010
The inter‐relationship of diabetes and left ventricular systolic function on outcome after high‐risk myocardial infarction
Shah AM, Uno H, Køber L, Velazquez EJ, Maggioni AP, MacDonald MR, Petrie MC, McMurray JJ, Califf RM, Pfeffer MA, Solomon SD. The inter‐relationship of diabetes and left ventricular systolic function on outcome after high‐risk myocardial infarction. European Journal Of Heart Failure 2010, 12: 1229-1237. PMID: 20965879, DOI: 10.1093/eurjhf/hfq179.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionRecurrent myocardial infarctionHF hospitalizationRisk of deathMyocardial infarctionCause mortalityHigh riskSpectrum of LVEFHigh-risk post-MI patientsBaseline left ventricular ejection fractionHigher left ventricular ejection fractionHigh-risk myocardial infarctionAcute Myocardial Infarction trialCox proportional hazards modelPost-MI populationHeart failure hospitalizationMyocardial Infarction trialNon-diabetic patientsVentricular systolic functionVentricular ejection fractionPost-MI patientsAcute myocardial infarctionPotent risk factorProportional hazards modelFailure hospitalizationPathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both
Pouleur AC, Barkoudah E, Uno H, Skali H, Finn PV, Zelenkofske SL, Belenkov YN, Mareev V, Velazquez EJ, Rouleau JL, Maggioni AP, Køber L, Califf RM, McMurray JJ, Pfeffer MA, Solomon SD. Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. Circulation 2010, 122: 597-602. PMID: 20660803, DOI: 10.1161/circulationaha.110.940619.Peer-Reviewed Original ResearchConceptsSudden unexpected deathRecurrent MISudden deathArrhythmic deathAutopsy recordsUnexpected deathAcute Myocardial Infarction trialImplantable cardioverter-defibrillator therapyEarly post-myocardial infarction periodPost-myocardial infarction periodMyocardial Infarction trialCardioverter-defibrillator therapySudden death eventsIndex MILack of benefitSeries of casesCardiovascular causesNoncardiovascular causesVentricular dysfunctionAcute MICardiac ruptureHeart failureAutopsy evidenceClinical groundsAutopsy findingsFatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT)
Shamshad F, Kenchaiah S, Finn PV, Soler-Soler J, McMurray JJ, Velazquez EJ, Maggioni AP, Califf RM, Swedberg K, Kober L, Belenkov Y, Varshavsky S, Pfeffer MA, Solomon SD, Investigators F. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). American Heart Journal 2010, 160: 145-151. PMID: 20598985, DOI: 10.1016/j.ahj.2010.02.037.Peer-Reviewed Original ResearchConceptsQ-wave myocardial infarctionMyocardial infarctionMyocardial ruptureClinical end-point committeeHigh-risk myocardial infarctionAcute Myocardial Infarction trialEnd-point committeeNonfatal cardiovascular eventsPresence of hemopericardiumQualifying MIMyocardial Infarction trialHigh-risk patientsGlomerular filtration ratePost-MI patientsAcute myocardial infarctionInferior myocardial infarctionDirect surgical visualizationKillip classCardiovascular eventsDiuretic useOral anticoagulantsVentricular dysfunctionClinical characteristicsFatal complicationHeart failureAtrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial
Nilsson KR, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober L, Granger CB, Lewis EF, McMurray JJ, Califf RM, Velazquez EJ. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart 2010, 96: 838. PMID: 20406769, DOI: 10.1136/hrt.2009.180182.Peer-Reviewed Original ResearchConceptsRhythm control strategyAcute Myocardial Infarction trialMyocardial Infarction trialAtrial fibrillationMyocardial infarctionRate control strategyEarly mortalityAnti-arrhythmic drug therapyTreatment of AFPeri-infarct periodIncidence of strokeManagement of patientsRisk of deathLate mortalityPatient populationDrug therapyCox modelPatientsMortalityInfarctionStrokeValsartanTrialsDeathDays
2009
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial
Moukarbel GV, Signorovitch JE, Pfeffer MA, McMurray JJ, White HD, Maggioni AP, Velazquez EJ, Califf RM, Scheiman JM, Solomon SD. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. European Heart Journal 2009, 30: 2226-2232. PMID: 19556260, DOI: 10.1093/eurheartj/ehp256.Peer-Reviewed Original ResearchConceptsRisk factorsGastrointestinal bleedingGI bleedingWorse New York Heart Association classNew York Heart Association classAcute Myocardial Infarction trialPost-myocardial infarction patientsAdditional antiplatelet drugsProfound risk factorRate of GIAdjusted hazard ratioDual antiplatelet therapyMultivariable Cox modelMyocardial Infarction trialDual antiplatelet agentsLeft ventricular dysfunctionGlomerular filtration rateHigh-risk survivorsUse of antiplateletPost-MI patientsRisk of deathPotential risk factorsNon-white racePresent secondary analysisOccurrence of GIUsefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial)
Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA. Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial). The American Journal Of Cardiology 2009, 104: 151-157. PMID: 19576338, DOI: 10.1016/j.amjcard.2009.03.020.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenergic beta-AntagonistsAgedAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionProspective StudiesRisk AssessmentRisk FactorsSurvival AnalysisTetrazolesTreatment OutcomeValineValsartanConceptsBeta blockersHeart failureMyocardial infarctionBaseline characteristicsAcute Myocardial Infarction trialAngiotensin receptor blocker valsartanCombination of valsartanNonfatal cardiovascular eventsAngiotensin receptor blockersBeta-blocker useMyocardial Infarction trialVentricular systolic dysfunctionHigh-risk patientsRisk of deathSignificant survival advantageCardiovascular eventsSystolic dysfunctionVentricular dysfunctionVentricular functionSurvival advantageLower riskPatientsMortality rateBlockersValsartanPatients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)
Berry C, Pieper KS, White HD, Solomon SD, Van de Werf F, Velazquez EJ, Maggioni AP, Califf RM, Pfeffer MA, McMurray JJ. Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). European Heart Journal 2009, 30: 1450-1456. PMID: 19346225, DOI: 10.1093/eurheartj/ehp102.Peer-Reviewed Original ResearchConceptsPrior CABG patientsCoronary artery bypassMyocardial infarctionCABG patientsPrior CABGHeart failureArtery bypassNon-Q-wave myocardial infarctionPrior coronary artery bypassAcute Myocardial Infarction trialPrimary percutaneous coronary interventionKaplan-Meier ratesSecondary preventive therapyWorse clinical profileMyocardial Infarction trialVentricular systolic dysfunctionHigh-risk patientsPercutaneous coronary interventionAcute myocardial infarctionNumber of patientsNon-fatal outcomesHospital presentationLess aspirinMore comorbiditiesCardiovascular deathChronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP, Investigators F. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal Of Heart Failure 2009, 11: 292-298. PMID: 19176539, PMCID: PMC2645058, DOI: 10.1093/eurjhf/hfp001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAtherosclerosisCause of DeathConfidence IntervalsDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionOdds RatioPrognosisProportional Hazards ModelsProspective StudiesPulmonary Disease, Chronic ObstructiveSurvival RateTetrazolesTime FactorsValineValsartanConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAcute Myocardial Infarction trialMyocardial Infarction trialPulmonary diseaseAcute myocardial infarctionAtherosclerotic eventsMyocardial infarctionIndependent predictorsCV outcomesHazard ratioNon-fatal clinical eventsNon-CV deathAdjusted hazard ratioMajor cardiovascular eventsHigh-risk patientsRisk of deathProportional hazards modelMode of deathMedian followCardiovascular eventsCause mortalityAirway diseaseMultivariate adjustmentUnadjusted risk
2008
High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
Anderson RE, Pfeffer MA, Thune JJ, McMurray JJ, Califf RM, Velazquez E, White HD, Rouleau JL, Skali H, Maggioni A, Solomon SD. High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal 2008, 155: 706-711. PMID: 18371480, DOI: 10.1016/j.ahj.2007.11.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCardiovascular DiseasesDiabetes ComplicationsFemaleHumansHypertensionKaplan-Meier EstimateMaleMiddle AgedMortalityMultivariate AnalysisMyocardial InfarctionProportional Hazards ModelsRisk FactorsSex FactorsSmokingSurvivorsTetrazolesValineValsartanConceptsAcute myocardial infarctionAcute Myocardial Infarction trialMyocardial Infarction trialRisk factorsMyocardial infarctionHigh-risk myocardial infarctionCardiovascular event ratesInfluence of hypertensionMultivariate Cox regressionPrognostic risk factorsHistory of MICardiovascular outcomesCurrent smokersLess diabetesYounger patientsCox regressionPost-AMIAdvanced ageRelative riskYoung survivorsAge groupsHypertensionEvent ratesPatientsOutcomes
2006
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience
Stephenson K, Skali H, McMurray JJ, Velazquez EJ, Aylward PG, Kober L, Van de Werf F, White HD, Pieper KS, Califf RM, Solomon SD, Pfeffer MA. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. Heart Rhythm 2006, 4: 308-313. PMID: 17341394, DOI: 10.1016/j.hrthm.2006.11.021.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBundle-Branch BlockCaptoprilElectrocardiographyFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPredictive Value of TestsProportional Hazards ModelsResearch DesignRisk FactorsStroke VolumeSurvival AnalysisSurvivorsTetrazolesTime FactorsTreatment OutcomeValineValsartanVentricular Dysfunction, LeftConceptsNew left bundle branch blockLeft bundle branch blockLV systolic dysfunctionHigh-risk survivorsHeart failureMyocardial infarctionBundle branch blockSystolic dysfunctionCardiovascular outcomesIndependent predictorsBranch blockLeft ventricular systolic dysfunctionLong-term cardiovascular complicationsMajor adverse cardiovascular outcomesAcute Myocardial Infarction trialBaseline ECG dataMajor cardiovascular outcomesPost-MI survivorsComposite of deathMyocardial Infarction trialVentricular systolic dysfunctionAdverse cardiovascular outcomesHigh-risk patientsLV ejection fractionLong-term outcomesGeographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
Reed SD, McMurray JJ, Velazquez EJ, Schulman KA, Califf RM, Kober L, Maggioni AP, Van de Werf F, White HD, Diaz R, Mareev V, Murin J, Committees and Investigators F. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal 2006, 152: 500-508. PMID: 16923421, DOI: 10.1016/j.ahj.2006.02.032.Peer-Reviewed Original ResearchConceptsHigh-risk patientsAcute myocardial infarctionMyocardial infarctionReperfusion therapyBaseline characteristicsVALIANT trialLeft ventricular systolic dysfunctionTime of MIAcute Myocardial Infarction trialSafety of captoprilMyocardial Infarction trialPatient baseline characteristicsUse of aspirinVentricular systolic dysfunctionProportion of patientsCare of patientsEvidence-based therapiesMultivariable regression modelsSystolic dysfunctionHeart failureTrial populationKey treatmentPatientsInternational trialInternational guidelinesThe Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M. The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Journal Of The American College Of Cardiology 2006, 47: 726-733. PMID: 16487836, DOI: 10.1016/j.jacc.2005.09.055.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina PectorisAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAtherosclerosisCaptoprilCardiovascular DiseasesDisease-Free SurvivalDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMyocardial InfarctionRandomized Controlled Trials as TopicRecurrenceStrokeTetrazolesValineValsartanConceptsAngiotensin receptor blockersAcute Myocardial Infarction trialMyocardial Infarction trialAtherosclerotic eventsMyocardial infarctionACE inhibitorsValsartan groupReceptor blockersEnzyme inhibitorsNon-fatal myocardial infarctionAngiotensin-converting enzyme inhibitorAnti-infarction effectSecondary preventive treatmentEffect of valsartanRenin-angiotensin systemBlood pressure differenceEffects of captoprilAcute myocardial infarctionCaptopril groupCombination groupPreventive treatmentLower riskEvidence gapsCaptoprilValsartan
2005
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, Investigators F. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American Heart Journal 2005, 150: 323-329. PMID: 16086938, DOI: 10.1016/j.ahj.2004.08.037.Peer-Reviewed Original ResearchMeSH KeywordsAmbulatory CareAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilDrug CostsGlobal HealthHealth Care CostsHealth ResourcesHeart FailureHospital CostsHospitalizationHumansMyocardial InfarctionProspective StudiesQuality of LifeTetrazolesValineValsartanVentricular Dysfunction, LeftConceptsQuality of lifeMyocardial infarctionAcute Myocardial Infarction trialLower medication costsMyocardial Infarction trialHealth-related qualityLinear mixed-effects regression analysisMultinational clinical trialsMixed-effects regression analysisCaptopril groupStudy medicationCardiovascular morbidityVentricular dysfunctionMost patientsHeart failureACE inhibitorsMedication costsProspective economic evaluationClinical trialsHigh riskPatientsValsartanResource useCaptoprilSignificant differences
2004
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. New England Journal Of Medicine 2004, 351: 1285-1295. PMID: 15385655, DOI: 10.1056/nejmoa041365.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilCardiovascular DiseasesChronic DiseaseCreatinineDouble-Blind MethodDrug Therapy, CombinationFemaleGlomerular Filtration RateHumansKidney DiseasesMaleMiddle AgedMyocardial InfarctionProportional Hazards ModelsRisk FactorsSurvival RateTetrazolesValineValsartanConceptsGlomerular filtration rateAcute myocardial infarctionMyocardial infarctionCardiovascular outcomesHeart failureRisk factorsAcute Myocardial Infarction trialFour-component ModificationNonfatal cardiovascular outcomesMyocardial Infarction trialUse of aspirinComposite cardiovascular eventsComposite end pointRenal Disease equationCongestive heart failureMild renal diseaseRisk of deathCoronary revascularization proceduresMajor risk factorSerum creatinine measurementsBody surface areaCardiovascular causesKillip classRenal eventsCardiovascular complicationsNewly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction
Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O’Connor C, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction. Circulation 2004, 110: 1572-1578. PMID: 15364810, DOI: 10.1161/01.cir.0000142047.28024.f2.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilCohort StudiesComorbidityDiabetes ComplicationsDiabetes MellitusDrug Therapy, CombinationFemaleFollow-Up StudiesHeart FailureHumansLife TablesMaleMedical RecordsMiddle AgedMulticenter Studies as TopicMyocardial InfarctionProportional Hazards ModelsRandomized Controlled Trials as TopicRiskStrokeTetrazolesTime FactorsTreatment OutcomeValineValsartanVentricular Dysfunction, LeftConceptsAcute myocardial infarctionMyocardial infarctionCardiovascular eventsDiabetes mellitusAdverse outcomesAcute Myocardial Infarction trialPoor long-term outcomesMajor cardiovascular eventsMyocardial Infarction trialHigh-risk patientsRisk of deathLong-term outcomesRisk of mortalityBaseline characteristicsDiabetic statusComorbid conditionsMetabolic abnormalitiesPrior diagnosisPoor prognosisNew diagnosisDiabetesPatientsMellitusOutcomesInfarction
2003
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context
Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau J, Van de Werf F, Kober L, White HD, Swedberg K, Leimberger JD, Gallo P, Sellers MA, Edwards S, Henis M, Califf RM, Investigators F. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. European Journal Of Heart Failure 2003, 5: 537-544. PMID: 12921816, DOI: 10.1016/s1388-9842(03)00112-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin Receptor AntagonistsCaptoprilDouble-Blind MethodFemaleGlyceraldehyde-3-Phosphate DehydrogenasesHeart FailureHumansMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionPeptide FragmentsRandomized Controlled Trials as TopicTetrazolesValineValsartanVentricular Dysfunction, LeftConceptsAcute Myocardial Infarction trialAngiotensin receptor blockadeMyocardial Infarction trialHeart failureMyocardial infarctionACEI trialsRenin-angiotensin system blockadePlacebo-controlled trialVentricular systolic dysfunctionActive-controlled trialEvidence-based careHigh-risk populationEvidence-based therapiesCardiovascular outcomesSystem blockadeSystolic dysfunctionBaseline characteristicsStandard treatmentRepresentative cohortPatientsMI trialsTrialsValsartanACEIsLVSD
2000
Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design
Pfeffer M, McMurray J, Leizorovicz A, Maggioni A, Rouleau J, Van de Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers M, Velazquez E, Califf R, Investigators* F. Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. American Heart Journal 2000, 140: 727-750. PMID: 11054617, DOI: 10.1067/mhj.2000.108832.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin IIAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilCause of DeathDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationHumansMulticenter Studies as TopicMyocardial InfarctionOdds RatioPatient SelectionProportional Hazards ModelsRandomized Controlled Trials as TopicResearch DesignSample SizeTetrazolesValineValsartanConceptsAngiotensin II receptor blockersII receptor blockersAcute myocardial infarctionMyocardial infarctionReceptor blockersVentricular dysfunctionHeart failureAngiotensin II receptor blocker valsartanEnzyme inhibitorsMajor nonfatal cardiovascular eventsAcute Myocardial Infarction trialAngiotensin-converting enzyme inhibitorDose of captoprilMultiple practice patternsNonfatal cardiovascular eventsUse of valsartanMyocardial Infarction trialReceptor blocker valsartanHigh-risk patientsLeft ventricular dysfunctionParallel-group studyRenin-angiotensin systemManagement of patientsCombination of captoprilLong-term treatment